Comparative Clinical Trial of Parenteral CO-Trimoxazole in Major Respiratory Infections

  • M. Janousek
  • L. Corbeel
  • P. Stenier
Part of the Chemotherapy book series (CT, volume 6)


The introduction of the trimethoprim-sulphamethoxazole combination (generic term: co-trimoxazole) heralded a certain renewal of antibiotic therapeutics. It is indeed not merely a matter of the administration of two drugs whose respective spectra more or less complete each other, but that of a synergic correlation in which the two constituents are reciprocally potentiated. This synergy phenomenon seems to result from the fact that the 2 constituents point of impact is situated at 2 consecutive levels in the metabolic sequence leading to tetrahydrofolic acid, an essential factor for the synthesis of certain nucleotidic compounds indispensable to the survival and development of very many bacterial species.


Comparative Clinical Trial Local Tolerance Double Blind Comparative Study Metabolic Sequence Tetrahydrofolic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    STRULLER Th.: Progress in Drug Research (1968), 12, 495 E. Jucker.Google Scholar
  2. 2.
    BOEHNI E.: Chemotherapy (1969), Suppl. 14, 1–83Google Scholar
  3. 3.
    BOEHNI E.: The Chemotherapeutic activity of combination of trimethoprim and sulfamethoxazole in infections of mice. Postgrad, med. J. (1969), Suppl. 45, 18Google Scholar
  4. 4.
    MCORHOUSE E.C., FARREL W.: Effect of co-trimoxazole on faecal enterobacteria: no energence of resistant strain. J. med. Microbiol. (1973), 6, 249.CrossRefGoogle Scholar
  5. 5.
    BUSHBY, S.R.M.: Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J. infect. Dis. 1973, Suppl. 128, S442.CrossRefGoogle Scholar
  6. 6.
    CORBEEL L., STENIER P.: Etude clinique on double anonymat de l’association sulfamethoxazole-trimethoprime dans les infections pulmonaires chroniques. V. Internationaler Kongress für Infektionskrankheiten, Wien 31 Aug.-5 Sept. 1970.Google Scholar
  7. 7.
    HOWELLS CH.L., TYLER L.E.: A comparative trial of ampicilliii, tetracycline and a combination of trimethoprim and sulfamethoxazole in the treatment of respiratory infections. Brit. J. clin. Pract. 1971, 25, 2Google Scholar
  8. 8.
    JILG S.: Erfahrungen mit Bactrim Roche bei der Behandlung akuter und chronischer Infektionen des respirationtraktes. Med. heute 1971, 20, 3, 5Google Scholar
  9. 9.
    BRUNINX M., DE KOSTER J.P., GOLARD P., LIBERT P., MINETTE A. MOTTARD L., REMARCLE P., ROBIENCE Y., SCHMITZ P. et VEREERSTRAETEN J.: Administration à titre prophylactique du Bactrim dans la bronchite chronique: étude clinique et biologique à double insu. Acta tuberc. pneumol. belg. 1973, 64, 483Google Scholar
  10. 10.
    HUGHES D.T.D.: Use of combinations of trimethoprim and sulfamethoxazole in the treatment of chest infections. J. infect. Dis. 1973, Suppl. 128, S701CrossRefGoogle Scholar
  11. 11.
    PINES A.: Trimethoprim-sulfamethoxazole in the treatment and prevention of purulent exacerbations of chronic bronchitis. J. Infect. Dis. 1973, Suppl. 128, S706.CrossRefGoogle Scholar
  12. 12.
    SANFORD CHODOSH, BERTRAM EICHEL, CHARLES ELLIS, TULLIO C. MEDICI and L. JACK FALING: Trimethoprim-sulfamethoxazole compared with ampicillin in acute infections exacerbations of chronic bronchitis. A double blind cross-over study. J. infect. Dis. 1973, Suppl. 128, S710.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • M. Janousek
    • 1
  • L. Corbeel
    • 1
  • P. Stenier
    • 1
  1. 1.Clinique St PierreOttigniesBelgium

Personalised recommendations